Floatz logo

Idursulfase Beta

Hunter Syndrome

GC Biopharma Corpprotein_peptidePhase 3Dormant
BBB
72/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
61/ 100
Competitive Position
95/ 100

Competitive context

23 Active assets in the Hunter Syndrome cohort.

Asset / SponsorPhaseRating
gc1111
Takeda
Phase 4A
PABINAFUSP ALFA
JCR Pharmaceuticals Co., Ltd.
Phase 3BBB
Rgx-121
REGENXBIO Inc.
Phase 3BB
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Takeda
Phase 4BB
Gnr-055
AO GENERIUM
Phase 2/3BB

View all 32 →

Same molecule, other indications

Idursulfase Beta is also rated in:

GC1111Dormant
BB
Indicative ·
64 / 100
View asset →
mucopolysaccharidosis type 2Dormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →